Comprehensive explanation of usage and dosage of Laos Lucius version of osimertinib

Osimertinib, as a targeted therapy drug designed specifically for epidermal growth factor receptor (EGFR) mutations, has occupied an important position in the treatment of non-small cell lung cancer in recent years. It provides a new treatment option for patients with EGFR mutation-positive non-small cell lung cancer. At present, Lucius Pharmaceuticals in Laos has successfully launched a generic version of osimertinib, which undoubtedly brings hope to more patients. However, many patients still have questions about the usage and dosage of this version. This article will introduce it in detail.

Osimertinib produced by Lucius Pharmaceuticals in Laos has strict guidelines on usage and dosage. For the adjuvant treatment ofEGFR mutation-positive non-small cell lung cancer, it is recommended that patients take it orally once a day at a dose of 80 mg. Patients can choose to take it with or without food according to their individual circumstances. This treatment regimen usually lasts for 3 years, or until the disease relapses or the patient develops intolerable toxicity.

For patients with locally advanced, unresectable (Stage III) EGFR mutation-positive non-small cell lung cancer, after completing platinum-based chemoradiotherapy, the Lao Lucious version of osimertinib is also recommended to be taken orally at 80 mg once daily until the disease progresses or the patient experiences unacceptable toxicity.

In the first-line treatment of EGFR mutation-positive metastatic non-small cell lung cancer, the usage and dosage of the Lao Lucius version of osimertinib remains unchanged. Patients take 80 mg orally once a day, with or without food. Treatment will continue until disease progression or the patient experiences unacceptable toxicity.

In addition, for the first-line treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer, the Laos version of osimertinib can also be used in combination with other drugs such as pemetrexed and platinum-based chemotherapy. In this combination regimen, the recommended dose of osimertinib remains 80 mg once daily. The presence or absence of food does not affect drug absorption and utilization, and treatment will continue until disease progression occurs or the patient develops unacceptable toxicity.

It is worth noting that the Laos Lucius version of osimertinib is not only reliable in quality, but also affordable. A box of 80mg*30 tablets sells for about five to six hundred yuan, which allows more patients to afford this important treatment and thus have the opportunity to receive more effective treatment. However, patients still need to strictly follow medical instructions during medication, regularly monitor their physical condition, and report any discomfort or abnormal symptoms to their doctor in a timely manner.

Reference materials:https://www.drugs.com/pro/tagrisso.html